Scientists are studying these strategies to develop an effective vaccines and deliver it into the body in a way that maximizes the immune response.
Vaccine Strategies in the Pipeline
HIV-Specific Neutralizing Antibodies – Targets and research status
Numerous studies, both early and late phase, are investigating the efficacy of neutralizing antibodies. This infographic shows the ongoing studies and the differing locations they target on the virus.
Total Vaccine Spending by Area
A look at the percentage of total funds invested in different aspects of vaccine research.
Vaccines Trial Participation in 2019
A look at the number of participants in vaccines trials in 2019 according to trial phase.
The Science of Choice: The future of HIV prevention research
This episode of Px Pulse features unmissable conversations about some of the challenges associated with today’s HIV prevention options, and analysis about what should be in the research pipeline from 2021 to 2027.
Regulatory Status of TDF/FTC for PrEP
The TDF/FTC combination pill (brand-name Truvada) that has shown efficacy for PrEP is already used for Treatment U=U in HIV-positive people, and so is approved and licensed in many countries. One key step for this PrEP strategy is to ensure that the drug is licensed (and therefore available) and that it is approved for use for both prevention and Treatment U=U in each country. National guidelines for PrEP use are another key step.
GPP @ 10
A decade ago, UNAIDS and AVAC published the Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials (GPP). Created to provide a consistent global standard for stakeholder engagement across the research life-cycle, GPP has emerged as a point of reference for how to engage stakeholders. It has also given rise to a robust community of practice.
After ten years of implementation, AVAC offers a look back at GPP and a vision for its future — and we explain why GPP’s true potential lies in the hands not just of research groups, but of civil society, trials participants, and an array of stakeholders in the research endeavor.
Community Engagement and HIV Prevention
In this episode of Px Pulse, we consider how future HIV prevention trials will need to be designed as HIV prevention evolves… and how to strengthen community engagement along with it. At the heart of the matter is that clinical trials for HIV prevention are set to get bigger and more complex, in response to advances in HIV prevention, such as PrEP.
Px Wire July-December 2018, Vol. 11, No 3
As 2018 winds down, we’re struck by the many moments, and movements, in the past year that have depended on listening, without bias and also without loss of conviction. In that spirit, our year-end edition of Px Wire offers 10 questions for activists to pose, with curiosity and conviction, in 2019. What answers do you want, what do you hear, what needs to happen next?
One Timeline, Two Stories, One Message: Putting trials and targets together
One problem with HIV prevention agendas is that they either live in an eternal present or in a far-off future. It’s “work with what we’ve got, which is condoms and VMMC and a little bit of PrEP”, or it’s “nothing can change without an AIDS vaccine”. The future depends on using what’s available, better and more widely, without ever losing sight of what’s in the pipeline.
As the figures below show, in the very same timeframe that the world will miss its critical target for incidence reduction and scale-up of primary prevention, several trials will release results that could change the future. 2020 will be a time of hope and reckoning. But only if the two stories start to be told as one.